DxS Signs a License with DiagnoCure for its Scorpions® Technology
DiagnoCure will gain access to Scorpions for the development of their GCC-based molecular test for colorectal cancer.
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer
Eden will manufacture MBP-DC-SIGN for Borean to use in key preclinical studies.
Increased Risk for Arthritis and Lupus Tied to new Gene
Scientists identify a critical gene that increases a person’s risk for rheumatoid arthritis and systemic lupus and may be involved in other autoimmune diseases.
Celera to Acquire Berkeley HeartLab
Acquisition provides Celera with CLIA-certified laboratory to commercialize its portfolio of new tests & vehicle to deliver personalized disease management in cardiovascular disease.
Philips and the Institute of Health Sciences Join Forces in Molecular Medicine
Royal Philips Electronics and IHS will create new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment.
Agendia Raises €25 Million and Receives Second FDA Clearance
ING, one of the largest bank-insurers, becomes a shareholder of Agendia.
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
BSD Medical Obtains Patent License for Primary Breast Cancer Treatment System from Duke University
BSD Medical gains exclusive rights to Duke’s treatment system for primary breast cancer using hyperthermia therapy.
A Study by the MUHC and McGill University Opens a new Door to Understanding Cancer
Study provides a key to understand the mechanisms that trigger cancer cell growth that may prove crucial to develop more targeted treatments for cancer.